The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
Financial terms of the acquisition were not disclosed.
Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.